趋势:西雅图最新的亿万富翁表示,税务谈话将驾驶业务,索引西雅图冻结是'垃圾'
Nautilus Biotechnology联合创始人Sujal Patel(左)和滑翔伞。(Nautilus照片)

鹦鹉螺Biotechnology,基于西雅图的Biotech启动,由Isilon联合创始人领导Sujal Patel.,是最新的公司使用特殊目的采集公司或SPAC。

交易,announced星期一早上将注入约3.5亿美元的鹦鹉螺,该鹦鹉螺正在开发一个分析人类蛋白质组或身体全套蛋白质的下一代平台。它将公司价值为9亿美元。

该公司计划将1.5亿美元的资金筹集为Arya Sciences收购公司的一部分,该公司是由现有的Nautilus投资者感染顾问赞助的公开交易SPAC。作为交易的一部分,Nautilus还将通过公共股权的私人投资从新的和以前的支持者卷起2亿美元,也称为普通股票,用于将SPAC作为额外的融资。

SPAC兼并已成为首次公开产品传统进程的流行替代品,提供了更快的公共道路。又称“空白支票”公司,SPAC通常没有建立的业务,用于通过公众提出资金,以便通过特定截止日期为未来的合并或收购。据据报道,据估计,去年筹集了730亿美元,据高盛萨克斯报告TechCrunch..

Perceptive, a top biotech investment firm, is sponsoring the SPAC. The boards of both Arya III and Nautilus have approved the proposed transaction, which is expected to close in the second quarter. The combined company will keep the Nautilus name and will be listed on the Nasdaq under the ticker NAUT.

帕尔和斯坦福教授成立于2016年Parag Mallick, Nautilus is building a combination of hardware and software to more accurately and efficiently quantify the human proteome. The 70-person company, co-located in Seattle and Silicon Valley, has an ambitious plan to change the way therapeutics are developed, seeking to catalyze a new wave of medical treatment.

“We believe that a radical reinvention of proteomics is necessary,” Patel said during an investor presentation Monday. “And we believe that Nautilus has the platform with the potential to revolutionize biomedicine.”

Patel and Mallick will continue leading Nautilus when the merger is completed, along with the existing leadership team.

(Nautilus investor presentation)

While it’s now relatively simple and cheap to analyze a genome with a drop of blood, the same progress hasn’t been made with the proteome — and that’s the opportunity Nautilus is looking to capture with what it describes as faster, cheaper, and more precise proteomic technologies.

Part of Nautilus’ secret sauce is the ability to crunch huge amounts of data required when reading a proteome and applying technology such as machine learning. That’s something Patel knows well from his experience at Isilon, a pioneering storage company that went public in 2006 and helped large organizations better manage massive datasets.

There are several use cases for the company’s technology, including therapeutics development and other proteomics applications. A majority of FDA-approved drugs target a protein, and knowing more about the proteome can help make the drug development process more efficient.

In some ways, Nautilus wants to democratize proteomics, similar to how companies such as publicly-traded biotech giant Illumina have done with genomics. The company estimates a total addressable market of more than $25 billion.

“我们认为这是今天生物科学的最后一个未开发的机会之一,”一位退伍岛西雅图科技企业家Patel表示,2010年以25亿美元的价格将Isilon卖给EMC。

鹦鹉螺raised去年增加了7600万系列B轮由Vulcan Capital领导,由已故的Microsoft联合创始人保罗艾伦创建的多亿美元控股公司。Bezos Expeditions,亚马逊创始人Jeff Bezos的VC ARM,也投入了VC,以及VILECTIVE ADVINGS,ANDREESSEN HOROWITZ,Madrona Venture Group等。

安德森、Madrona和火神参与the PIPE, as well as new backers such as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., and Casdin Capital.

Nautilus在西雅图的马来斯州办事处享有早期的日子。Patel是该公司的战略主任。

Patel表示,SPAC在一步中给出Nautilus是一个更直接的IPO路径,而且与有风险支持的私人回合和传统的IPO的两步或三步过程。“

根据投资者介绍的预测,预计今年4600万美元的预计,额外现金将有助于加速Nautilus的商业化路径。收入预计到2025年将增长至1.83亿美元,但该公司仍然无利可图,估计净亏损4200万美元。

上个月鹦鹉螺announcedthree executive hires, including two of Patel’s former colleagues at Isilon. Late last year it also signed its first pharma partnership with Genentech for a pilot study.

鹦鹉螺’ SPAC deal follows a public offering last week for another Seattle biotech startup, Sana, whichraised$587.5 million and saw shares climb 40% on its first day of trading.

Other Seattle-area companies are getting in on the SPAC craze. In December, Seattle home services tech company Porch raised more than $322 millionthrough a merger上周使用PROPTECH收购公司,无线先锋CRAIG MCCAW的西雅图区域SPAC HOLICITY与卫星发射公司Astra合并.

喜欢你在读什么?订阅Geekwire的免费新闻通讯以捕捉每个标题

Geekwork上的工作列表

找到更多的工作GeekWork. Employers,岗位.